Syndax Begins New Chapter As A Late-Stage Drug Developer
This article was originally published in The Pink Sheet Daily
Executive Summary
A recent influx of cash to the small biotech will allow Syndax to develop its oncology asset on its own, beginning with a Phase III trial and potentially continuing to U.S. commercialization.